Name | Title | Contact Details |
---|
Rib-X Pharmaceuticals, Inc. is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy with 28 years of innovative excellence and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. BioPlus earned a #1 patient satisfaction ranking in both oncology and hepatitis C in Zitter`s Specialty Pharmacy Patient Satisfaction Survey. Our RxExpress program moves each prescription through our system in the most streamline way. From the 2-Hour Patient Acceptance Guarantee at the beginning to the 2-Day Ready 2 Ship at the end, along with free overnight shipping, physicians and patients can trust BioPlus to provide effective service that`s delivered fast. By keeping the wait time for medications as short as possible, patients don`t have to wait to get back to living their lives. BioPlus provides a complete range of specialty services, including for cancer, hepatitis C, multiple sclerosis, rheumatoid arthritis, dermatology, and other complex, chronic conditions. We are a privately-held, pharmacist-owned company based in Altamonte Springs, Florida and accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.`
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Boc Sciences is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.